Switching from protease inhibitors to efavirenz: differences in efficacy and tolerance among risk groups: a case–control study from the Swiss HIV Cohort-Reference-Cited by-同舟云学术

Switching from protease inhibitors to efavirenz: differences in efficacy and tolerance among risk groups: a case–control study from the Swiss HIV Cohort

Published:2002-02 Issue:3 Volume:16 Page:381-385
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:AIDS

Author:

Hirschel Bernard,Flepp Markus,Bucher Heiner C.,Zellweger Claudine,Telenti Amalio,Wagels Thomas,Bernasconi Enos,Ledergerber Bruno

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference8 articles.

1. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study

2. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort study

3. Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in Adults

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efavirenz and the CNS: what we already know and questions that need to be answered;Journal of Antimicrobial Chemotherapy;2015-07-22

2. Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir;Journal of Antimicrobial Chemotherapy;2011-06-01

3. Efavirenz;Kucers' The Use of Antibiotics Sixth Edition;2010-10-29

4. Association of HIV transmission categories with sociodemographic, viroimmunological and clinical parameters of HIV-infected patients;Epidemiology and Infection;2009-11-27

5. HIV Therapeutics: Antiretroviral Drugs and Immune-Based Therapies;National Institute of Allergy and Infectious Diseases, NIH;2009